A3P Biomedical AB is a Swedish company with a global mission – to radically improve precision in prostate cancer diagnostics and treatment.
The company’s leading product is Stockholm3, a clinically and commercially validated blood test for early detection of aggressive prostate cancer. The test has been developed by researchers at Karolinska Institutet.
The company has a wholly owned subsidiary laboratory for analyzing Stockholm3. The laboratory works in accordance with the Patient Safety Act 2010: 659 and is registered as a care provider with the Swedish Health and Care Inspectorate (IVO).
A3P Biomedical also has a wholly owned subsidiary that provides algorithm-based test results in a cloud-based system for handling clinical data in accordance with GDPR. The company is ISO 13485 certified and the software complies with IEC 62304 standard for medical technology software.